PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) announced a major leadership transition Monday, elevating President Carolyn Bonner to Chief Financial Officer as the company continues advancing a slate of clinical programs aimed at developing novel, non-invasive cancer treatments.
Bonner, who has served as Acting CFO since September 12, 2025, steps into the permanent role following the resignation of longtime Chief Financial Officer and company co-founder James “Jim” Quinlan, who stepped down for health reasons after taking medical leave earlier this year. The company described Bonner’s dual appointment as a move designed to streamline financial and operational decision-making at a pivotal point in its clinical development pipeline.
“Carolyn has been providing strong financial leadership since stepping in as acting CFO in September,” said Dr. Raza Bokhari, Medicus’ Executive Chairman and CEO. He added that consolidating the company’s financial and operational oversight under a single leader would enhance stability and continuity as Medicus pushes forward with its next stages of development.
Quinlan, credited with helping guide Medicus through its reverse takeover of Skinject, Inc. and its U.S. IPO and Nasdaq listing in 2024, received acknowledgment from the company for his foundational role.
Bonner brings nearly two decades of experience in healthcare, diagnostics, and corporate development, including leadership positions at PCL, Inc., Rosetta Genomics, and Inform Diagnostics. She holds a Bachelor of Science in Marketing from West Chester University of Pennsylvania.
Her expanded responsibilities include oversight of financial reporting, budgeting, forecasting, capital markets strategy, and treasury operations, while continuing to lead strategic planning and coordinate clinical and corporate development initiatives.
The leadership change comes as Medicus progresses through several significant milestones in its SkinJect clinical program. The company is conducting a Phase 2 proof-of-concept study (SKNJCT-003) in the United States using dissolvable microneedle arrays to non-invasively treat basal cell carcinoma. Early analysis released in March 2025 showed more than 60% clinical clearance, though the company emphasized that the results were preliminary.
Medicus also recently launched a parallel clinical trial in the United Arab Emirates and secured regulatory approval to expand the SKNJCT-003 study into the United Kingdom after a comprehensive review by the Medicines and Healthcare products Regulatory Agency and other oversight bodies.
Additionally, Medicus has undertaken strategic partnerships and acquisitions designed to broaden its therapeutic platform. In August 2025, the company signed a memorandum of understanding with Helix Nanotechnologies to explore co-development of thermostable mRNA vaccines. That same month, Medicus completed its acquisition of Antev Limited, adding Teverelix, a next-generation GnRH antagonist, to its pipeline for patients with advanced prostate cancer and conditions related to prostate enlargement.
Medicus also advanced patient-community initiatives this year, announcing a collaboration with the Gorlin Syndrome Alliance to expand compassionate access to its investigational SkinJect technology for individuals suffering from nevoid basal cell carcinoma syndrome.
The company said Bonner’s leadership positions her to integrate these expanding clinical, regulatory, and corporate efforts as Medicus navigates the next phase of its precision-guided biotech strategy.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.